Lymphangiogenesis, a potential treatment target for myocardial injury

Microvasc Res. 2023 Jan:145:104442. doi: 10.1016/j.mvr.2022.104442. Epub 2022 Oct 4.

Abstract

The lymphatic vascular system is crucial for the regulation of tissue fluid homeostasis, lipid metabolism, and immune function. Cardiac injury quickly leads to myocardial edema, cardiac lymphatic dysfunction, which ultimately results in myocardial fluid imbalance and cardiac dysfunction. Therefore, lymphangiogenesis-targeted therapy may improve the recovery of myocardial function post cardiac ischemia as observed in myocardial infarction (MI). Indeed, a promising strategy for the clinical treatment of MI relies on vascular endothelial growth factor-C (VEGF-C)-targeted therapy, which promotes lymphangiogenesis. However, much effort is needed to identify the mechanisms of lymphatic transport in response to heart disease. This article reviews regulatory factors of lymphangiogenesis, and discusses the effects of lymphangiogenesis on cardiac function after cardiac injury and its regulatory mechanisms. The involvement of stem cells on lymphangiogenesis was also discussed as stem cells could differentiate into lymphatic endothelial cells (LECs) and stimulate phenotype of LECs.

Keywords: Lymphangiogenesis; Lymphatic endothelial cells; Lymphatic vessel; Myocardial infarction; Vascular endothelial growth factor-C.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Endothelial Cells / metabolism
  • Humans
  • Lymphangiogenesis
  • Lymphatic Vessels* / metabolism
  • Myocardial Infarction* / metabolism
  • Myocardial Ischemia* / metabolism
  • Myocardium / metabolism
  • Vascular Endothelial Growth Factor C / metabolism

Substances

  • Vascular Endothelial Growth Factor C